ExiVex Biopharma, Inc.
ExiVex Biopharma, Inc. develops emergency-grade intranasal drug delivery systems for rapid administration of critical medications in central nervous system (CNS) emergencies. The company’s proprietary dual-chamber intranasal platform is designed to deliver bioavailability close to intravenous administration, without needles and requiring no medical training. Their lead program aims to address urgent therapeutic needs in opioid overdose, seizures, migraines, and similar acute CNS events, with a focus on regulatory efficiency and manufacturing scalability.
Industries
N/A
ExiVex Biopharma, Inc.
Products
Proprietary device system that separately stores drug and excipient, mixing them at administration to enable rapid, high-bioavailability nasal delivery.
Lead product candidate for opioid overdose reversal using dual-chamber device delivering naloxone intranasally with IV-approaching bioavailability and rapid onset.
Proprietary device system that separately stores drug and excipient, mixing them at administration to enable rapid, high-bioavailability nasal delivery.
Lead product candidate for opioid overdose reversal using dual-chamber device delivering naloxone intranasally with IV-approaching bioavailability and rapid onset.
Services
Provision of the dual-chamber intranasal delivery platform for co-development, out-licensing, or collaborative product development in acute CNS indication areas.
Provision of the dual-chamber intranasal delivery platform for co-development, out-licensing, or collaborative product development in acute CNS indication areas.
Expertise Areas
- Intranasal drug delivery
- Emergency pharmacology
- Pharmacokinetics
- CNS-active therapeutics
Key Technologies
- Dual-chamber intranasal delivery
- Venturi atomization
- pH-optimized excipient formulation
- Point-of-use mixing technology
Key People
Chairman & Co-founder
CEO & Co-founder
CSO & Co-founder
CMO & Co-founder
Chairman & Co-founder
CEO & Co-founder
CSO & Co-founder
CMO & Co-founder
News & Updates
Secured IRB approval to initiate a crossover pharmacokinetic study of intranasal naloxone; enabled clinical data collection.
Filed foundational intellectual property protecting the dual-chamber intranasal device platform.
Discussion about reinventing overdose rescue technology with advanced intranasal delivery solutions.
Explaining how advanced intranasal technology achieves intravenous-like speed and relevance in the fentanyl overdose era.
CEO presented at the 19th annual LD Micro Main Event in San Diego, discussing the company's platform and programs.
International patent application covering dual/multi-chamber device architecture and point-of-use drug-excipient mixing.
Secured IRB approval to initiate a crossover pharmacokinetic study of intranasal naloxone; enabled clinical data collection.
Filed foundational intellectual property protecting the dual-chamber intranasal device platform.
Discussion about reinventing overdose rescue technology with advanced intranasal delivery solutions.
Explaining how advanced intranasal technology achieves intravenous-like speed and relevance in the fentanyl overdose era.
CEO presented at the 19th annual LD Micro Main Event in San Diego, discussing the company's platform and programs.
International patent application covering dual/multi-chamber device architecture and point-of-use drug-excipient mixing.